Free Trial

Jason Mills Analyst Performance

Analyst at Canaccord Genuity Group

Jason Mills is a stock analyst at Canaccord Genuity Group in the healthcare sector, covering 15 publicly traded companies. Over the past year, Jason Mills has issued 3 stock ratings, including buy and hold recommendations. While full access to Jason Mills' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason Mills' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
128 Last 12 Years
Buy Recommendations
84.25% 107 Buy Ratings
Companies Covered
15 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy84.3%107 ratings
Hold15.7%20 ratings
Sell0.0%0 ratings

Out of 127 total stock ratings issued by Jason Mills at Canaccord Genuity Group, the majority (84.3%) have been Buy recommendations, followed by 15.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
80.0% of companies on NASDAQ
12 companies
NYSE
20.0% of companies on NYSE
3 companies

Jason Mills, an analyst at Canaccord Genuity Group, currently covers 15 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
15 companies
100.0%

Jason Mills of Canaccord Genuity Group specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
HEALTHCARE EQUIPMENT & SUPPLIES
15 companies
100.0%

Jason Mills' Ratings History at Canaccord Genuity Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
11/6/2026Boost Price Target$68.98$120.00Buy
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
10/13/2026Lower Price Target$79.17$94.00Buy
Penumbra, Inc. stock logo
PEN
Penumbra
1/20/2026Downgrade$350.93$374.00Hold
Penumbra, Inc. stock logo
PEN
Penumbra
7/30/2025Set Price Target$227.26$350.00Buy
Penumbra, Inc. stock logo
PEN
Penumbra
2/19/2025Boost Price Target$299.18$340.00Buy